CN102834011B - 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗 - Google Patents

使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗 Download PDF

Info

Publication number
CN102834011B
CN102834011B CN201180009408.XA CN201180009408A CN102834011B CN 102834011 B CN102834011 B CN 102834011B CN 201180009408 A CN201180009408 A CN 201180009408A CN 102834011 B CN102834011 B CN 102834011B
Authority
CN
China
Prior art keywords
obstacle
purposes
disease
day
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180009408.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102834011A (zh
Inventor
Y·科亨
N·谢尔
I·门德尔
N·雅各布
E·布赖特巴特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANALIS-HAEMALIS BIOGROWTH Ltd
Original Assignee
CANALIS-HAEMALIS BIOGROWTH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANALIS-HAEMALIS BIOGROWTH Ltd filed Critical CANALIS-HAEMALIS BIOGROWTH Ltd
Publication of CN102834011A publication Critical patent/CN102834011A/zh
Application granted granted Critical
Publication of CN102834011B publication Critical patent/CN102834011B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180009408.XA 2010-01-05 2011-01-05 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗 Expired - Fee Related CN102834011B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US29222610P 2010-01-05 2010-01-05
US61/292,226 2010-01-05
US28225010P 2010-01-07 2010-01-07
US61/282,250 2010-01-07
US35197510P 2010-06-07 2010-06-07
US61/351,975 2010-06-07
US38931810P 2010-10-04 2010-10-04
US61/389,318 2010-10-04
US42311210P 2010-12-15 2010-12-15
US61/423,112 2010-12-15
PCT/IL2011/000008 WO2011083465A1 (en) 2010-01-05 2011-01-05 Treatment with vb-201

Publications (2)

Publication Number Publication Date
CN102834011A CN102834011A (zh) 2012-12-19
CN102834011B true CN102834011B (zh) 2016-01-13

Family

ID=44305239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180009408.XA Expired - Fee Related CN102834011B (zh) 2010-01-05 2011-01-05 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗

Country Status (13)

Country Link
US (4) US20120329758A1 (enExample)
EP (2) EP2521454A4 (enExample)
JP (2) JP2013516457A (enExample)
KR (1) KR20120133375A (enExample)
CN (1) CN102834011B (enExample)
AU (1) AU2011204406B2 (enExample)
BR (1) BR112012016543A2 (enExample)
CA (1) CA2786060A1 (enExample)
ES (1) ES2654944T3 (enExample)
MX (1) MX2012007807A (enExample)
NZ (1) NZ601224A (enExample)
WO (3) WO2011083469A1 (enExample)
ZA (1) ZA201205425B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
EP2348864A4 (en) * 2008-10-08 2013-07-31 Vascular Biogenics Ltd OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF
EP2826370A3 (en) 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
CA2847218C (en) * 2011-09-01 2018-02-27 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids
ES2758923T3 (es) * 2011-12-12 2020-05-07 Vascular Biogenics Ltd Tratamiento de esteatohepatitis no alcohólica
EP2814497A4 (en) * 2012-02-16 2015-12-09 Vascular Biogenics Ltd METHOD FOR TREATING PSORIASIS AND VESSEL IGNITION
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
EP3223824B1 (en) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
WO2017173203A1 (en) * 2016-03-31 2017-10-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing intestinal permeability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529605A (zh) * 2000-11-24 2004-09-15 预防和治疗动脉粥样硬化的应用方法和含有限定的氧化磷脂的组合物
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
CN1826122A (zh) * 2003-05-27 2006-08-30 脉管生物生长有限公司 氧化脂质及其在治疗炎性疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084209B2 (en) * 2005-07-22 2011-12-27 Children's Hospital & Research Center Oakland HMGCR isoforms in prediction of efficacy and identification of cholesterol-modulating compounds
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529605A (zh) * 2000-11-24 2004-09-15 预防和治疗动脉粥样硬化的应用方法和含有限定的氧化磷脂的组合物
CN1826122A (zh) * 2003-05-27 2006-08-30 脉管生物生长有限公司 氧化脂质及其在治疗炎性疾病中的应用
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids

Also Published As

Publication number Publication date
EP2521569B1 (en) 2017-11-01
EP2521569A1 (en) 2012-11-14
AU2011204406A1 (en) 2012-08-02
KR20120133375A (ko) 2012-12-10
EP2521454A4 (en) 2013-06-26
WO2011083469A1 (en) 2011-07-14
WO2011083467A1 (en) 2011-07-14
CN102834011A (zh) 2012-12-19
US20130225525A1 (en) 2013-08-29
EP2521454A1 (en) 2012-11-14
NZ601224A (en) 2015-03-27
CA2786060A1 (en) 2011-07-14
US20130172294A1 (en) 2013-07-04
JP2013516455A (ja) 2013-05-13
US20120329758A1 (en) 2012-12-27
AU2011204406B2 (en) 2015-05-07
WO2011083465A1 (en) 2011-07-14
ZA201205425B (en) 2015-07-29
ES2654944T3 (es) 2018-02-15
BR112012016543A2 (pt) 2015-09-01
EP2521569A4 (en) 2013-05-22
JP2013516457A (ja) 2013-05-13
MX2012007807A (es) 2012-10-03
US20160008381A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
CN102834011B (zh) 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗
US20230270746A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP2017518357A (ja) （２Ｒ，５Ｓ，１３ＡＲ）−８−ヒドロキシ−７，９−ジオキソ−Ｎ−（２，４，６−トリフルオロベンジル）−２，３，４，５，７，９，１３，１３Ａ−オクタヒドロ−２，５−メタノピリド［１’，２’：４，５］ピラジノ［２，１−ｂ］［１，３］オキサゼピン−１０−カルボキサミドの結晶形
TW202541800A (zh) 化合物之調配物及其用途
JP2018535939A (ja) Ｎａｓｈ関連肝臓癌を治療するためのｅｐ４受容体拮抗薬の使用
JP2023502067A (ja) 癌治療のためのｂｔｋ阻害剤及びｍｄｍ２阻害剤の組合せ
TW202532085A (zh) 醫藥配方及其用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
JP2007530688A (ja) 肝毒性が減少した組成物
WO2018013625A1 (en) Deuterated miconazole
HK1179118A (en) Treatment with vb-201
TW201309288A (zh) 鎮痛劑
JPS61251622A (ja) 胃粘膜　細胞を保護するアスピリン含有組成物
JP7848121B2 (ja) 感冒剤及び抗ウイルス剤
RU2806172C1 (ru) Состав, обладающий антиретровирусной активностью, фармацевтическая композиция и лекарственное средство
CN104434850B (zh) 一种含有阿德福韦酯的口服固体药物组合物
US20190142786A1 (en) Methods of treating obesity in responder and non-responder populations
JPS60228414A (ja) １２−リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
US12152008B2 (en) Cyclopentaimidazolones for the treatment of cancer
JP5366386B2 (ja) 神経細胞賦活及び神経伸長促進用組成物
CN101486655A (zh) 甲磺酸雷沙吉兰晶形及其制备方法
CN101411697A (zh) 一种治疗心血管疾病的药物组合物
JPH01216931A (ja) 血中尿酸濃度低減用治療剤
GB2047092A (en) Hypolipideamic agents containing methyl L-methionine sulfonium salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179118

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: Israel Yehuda

Patentee after: VASCULAR BIOGENICS LTD.

Address before: Israel Orr Yehuda

Patentee before: VASCULAR BIOGENICS LTD.

CP02 Change in the address of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160113

CF01 Termination of patent right due to non-payment of annual fee